FY2025 Earnings Estimate for Pfizer Inc. Issued By Leerink Partnrs (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) – Equities research analysts at Leerink Partnrs lifted their FY2025 EPS estimates for shares of Pfizer in a report issued on Thursday, May 2nd. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will post earnings per share of $2.93 for the year, up from their prior forecast of $2.68. The consensus estimate for Pfizer’s current full-year earnings is $2.28 per share. Leerink Partnrs also issued estimates for Pfizer’s FY2028 earnings at $2.69 EPS.

A number of other equities analysts have also recently commented on PFE. Morgan Stanley lifted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday. Guggenheim assumed coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Thursday. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $36.00.

Pfizer Stock Up 0.4 %

PFE stock opened at $27.81 on Friday. Pfizer has a 1-year low of $25.20 and a 1-year high of $40.37. The business’s 50 day simple moving average is $26.88 and its 200 day simple moving average is $28.25. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $157.48 billion, a PE ratio of -463.42, a PEG ratio of 1.20 and a beta of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. Pfizer’s quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the company posted $1.23 earnings per share.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.04%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s payout ratio is presently -2,799.53%.

Institutional Trading of Pfizer

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. raised its holdings in shares of Pfizer by 40.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after buying an additional 1,365,295 shares in the last quarter. LifePlan Financial LLC acquired a new position in Pfizer during the fourth quarter worth about $255,000. ETF Store Inc. lifted its holdings in shares of Pfizer by 12.0% in the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 727 shares during the last quarter. KLCM Advisors Inc. boosted its stake in shares of Pfizer by 75.0% in the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after purchasing an additional 74,487 shares in the last quarter. Finally, Farmers Trust Co. increased its position in Pfizer by 2.0% during the 4th quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock worth $6,503,000 after purchasing an additional 4,410 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.